Here are four things to know.
1. PharMEDium identified the potentially contaminated drugs after conducting a retrospective review of all medications compounded at the company’s Memphis, Tenn. location, per the FDA’s request.
2. The recall involves 25,327 units of drug products, which were distributed to hospitals and clinics nationwide.
3. The recalled drugs include various formulations of the pain medications fentanyl citrate and morphine sulfate.
4. PharMEDium has not received any reports of adverse effects related to the recalled products.
More articles on supply chain:
FDA ends 2017 with 46 new drug approvals – the most in 2 decades
Allergan to cut more than 1k jobs: 3 things to know
Drugmakers’ annual price hikes lower in 2018 than previous years: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
